1. **POLICY STATEMENT**
   1.1. Providing immunization to residents of Nova Scotia is a responsibility shared between the Department of Health and Wellness (DHW), the Nova Scotia Health Authority (NSHA), the Izaak Walton Killam Health Centre (IWK), primary care providers and health care organizations.
   1.2. The Department of Health and Wellness (DHW) provides policies, standards, and guidelines for each of the vaccine programs and procures the vaccines/immunoglobulins to be included in the publicly funded program.
   1.3. NSHA, the IWK, primary care providers and health care organizations implement the programs to Nova Scotians in adherence with those policies, standards, and guidelines.

2. **DEFINITIONS**
   2.1. N/A

3. **POLICY OBJECTIVES**
   3.1. To protect residents of Nova Scotia and others as identified in the policy from vaccine preventable diseases.
   3.2. To provide guidance for public health providers and other immunization providers to identify which vaccines/immunoglobulins are publicly funded in Nova Scotia and who is eligible to receive them.

4. **APPLICATION**
   4.1. This policy applies to all public health and other immunization providers who provide publicly funded vaccine.
5. POLICY DIRECTIVES

Eligibility
5.1. Residents of Nova Scotia
5.1.1. All residents of Nova Scotia with a valid Nova Scotia health card are eligible to receive publicly funded vaccines/immunoglobulins as described in Appendix A.

5.1.2. Individuals who have become residents of Nova Scotia and started an immunization series out of province:
   • Will finish the series as appropriate based on the Nova Scotia schedule.
   • Will follow the same eligibility as residents of Nova Scotia, regardless of eligibility out of province.

5.2. Visitors and/or Temporary Residents
5.2.1. Vaccines/immunoglobulins, with the exception of the influenza vaccine, are not routinely provided through the publicly funded immunization program to visitors or temporary residents of Nova Scotia.

5.2.2. The eligibility criteria for these individuals may change based on their circumstances.

5.2.3. A risk assessment approach in consultation with the Medical Officer of Health is to be used when making a decision regarding immunization of non-residents with publicly funded vaccines.

5.3. School-Based Program
5.3.1. Youth who have moved to Nova Scotia are eligible for each of the vaccines included in the school-based program:
   1) if they would have been in grade 7 (regardless of where they lived) at the time each of the vaccines were added to the school-based program. (For example, HPV for males in grade 7 was implemented in 2015); and
   2) if they are less than 19 years of age.

5.3.2. Youth who have missed or refused immunizations included in the school-based program are eligible for each of the vaccines:
   1) if they would have been in grade 7 at the time the missed or refused vaccine was added to the school-based program (For example, HPV for males in grade 7 was implemented in 2015); and
   2) if they are less than 19 years of age.

6. POLICY GUIDELINES

6.1. Publicly funded vaccines may be provided through the publicly funded program to residents/non-residents of Nova Scotia as part of outbreak/pandemic management, contact management or prevention of communicable diseases in high-risk populations more susceptible regardless of residency status: immigrants, refugees and other individuals establishing residency in Nova Scotia.

6.2. Regardless of residency status, individuals who have started a series of immunizations as part of post exposure immunization out of province will be able to have the series completed in Nova Scotia.

6.3. Products included in Appendix A may vary based on national contracts and availability.

7. ACCOUNTABILITY

7.1. For the purpose of the administration of this policy, accountability is delegated to the Deputy Minister of Health and Wellness.

7.2. DHW Public Health has responsibility to ensure the policy is current, evidence informed and reviewed every two years and for on-going monitoring and enforcement of this policy.
7.3. The NSHA and the IWK are accountable to ensure this policy is communicated to public health staff and other immunization providers within NSHA and the IWK respectively.

7.4. Public Health staff and other immunization providers who provide publicly funded immunizations are responsible for adhering to this policy.

8. MONITORING / OUTCOME MEASUREMENT
8.1. DHW Public Health is responsible for defining strategic outcomes, and monitoring performance and effectiveness of this policy.

8.2. The NSHA and the IWK are responsible for monitoring the implementation of this policy.

9. REPORTS
9.1. N/A

10. REFERENCES


11. APPENDICES
11.1. Appendix A: Nova Scotia Publicly Funded Vaccine/Immunoglobulin Eligibility

12. VERSION CONTROL
Version 11 October 2023, replaces all previous versions.

13. INQUIRIES
Health Protection, Public Health Branch
Nova Scotia Department of Health & Wellness
Email: cdpc@novascotia.ca
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>National Active Immunizing Agent (Type)</th>
<th>Vaccine Products e.g.</th>
<th>Eligibility</th>
</tr>
</thead>
</table>
| DTaP-IPV-Hib | Diphtheria, tetanus toxoid, acellular pertussis, inactivated polio, haemophilus influenzae type b | Pediacel | • Routine immunization of children 2 months to less than 7 years of age  
  o Note: Hib is not routinely indicated in children 5 years of age and older  
  • *Re-immunization of individuals 7 years of age and older post Hematopoietic Stem Cell Transplant (HSCT) |
| Tdap IPV     | Tetanus toxoid, diphtheria, acellular pertussis, inactivated polio | Adacel Polio Boostrix Polio | • Routine immunization booster for children 4 years to less than 7 years of age  
  • Immunization of individuals 7 years to less than 18 years of age who are unimmunized or have incomplete immunization  
  • Immunization of adults who are unimmunized |
| Tdap         | Tetanus toxoid, diphtheria, acellular pertussis | Adacel Boostrix | • Grade 7 students (school-based immunization program)  
  • Youth who have missed or refused Tdap vaccine as part of the school-based program, less than 19 years of age  
  • Pregnant women, in every pregnancy, irrespective of previous Tdap history  
  • Immunization of individuals 18 years of age and older who are unimmunized or have incomplete immunization  
  • Adults who require a tetanus or pertussis vaccine and have not received a pertussis containing vaccine in adulthood should receive a single dose of Tdap |
| Td           | Tetanus toxoid, diphtheria | Td adsorbed | • Adult booster every 10 years following one dose of Tdap as an adult  
  • Post-exposure immunization and wound management |
| HA           | Hepatitis A | Havrix Vaqta | • Post-exposure immunization  
  • Outbreak control  
  • *Pre-exposure immunization for those at increased risk of infection or severe Hepatitis A:  
    o Chronic liver disease  
    o Men who have sex with men  
    o High risk sexual practices  
    o HIV  
    o Substance use or harmful use of alcohol  
    o Individuals receiving repeated replacement of plasma derived clotting factors  
    o Children 6 months to less than 3 years of age who are living in a household with an individual who is at increased risk of infection or severe Hepatitis A |

*Refer to the publicly funded vaccine eligibility for individuals at high risk of acquiring vaccine preventable disease policy for eligibility criteria.
### Appendix A: Nova Scotia Publicly Funded Vaccine/Immunoglobulin Eligibility

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>National Active Immunizing Agent (Type)</th>
<th>Vaccine Products e.g.</th>
<th>Eligibility</th>
</tr>
</thead>
</table>
| HB           | Hepatitis B                             | Engerix               | • Grade 7 students (school-based immunization program)  
|              |                                        | Recombivax            | • Youth who have missed or refused HB vaccine as part of the school-based program, less than 19 years of age  
|              |                                        |                       | • Post-exposure immunization  
|              |                                        |                       | • Outbreak control  
|              |                                        |                       | • *Pre-exposure immunization for those at increased risk of Hepatitis B infection or severe Hepatitis B:  
|              |                                        |                       |   o Chronic liver disease  
|              |                                        |                       |   o Men who have sex with men  
|              |                                        |                       |   o Chronic renal disease  
|              |                                        |                       |   o Congenital immunodeficiency  
|              |                                        |                       |   o Hematopoietic stem cell transplant (HSCT)  
|              |                                        |                       |   o Hemophilia and other bleeding disorders  
|              |                                        |                       |   o High risk sexual practices  
|              |                                        |                       |   o HIV  
|              |                                        |                       |   o Substance use or harmful use of alcohol  
|              |                                        |                       |   o Solid organ transplant  
|              |                                        |                       |   o Splenic disorders including sickle cell disease or other hemoglobinopathies  
| HAHB         | Hepatitis A and B                       | Twinrix               | • *Pre-exposure immunization for those at increased risk of Hepatitis A and Hepatitis B infection or severe Hepatitis A and Hepatitis B:  
|              |                                        |                       |   o Chronic liver disease  
|              |                                        |                       |   o Men who have sex with men  
|              |                                        |                       |   o High risk sexual practices  
|              |                                        |                       |   o HIV  
|              |                                        |                       |   o Substance use or harmful use of alcohol  

*Refer to the publicly funded vaccine eligibility for individuals at high risk of acquiring vaccine preventable disease policy for eligibility criteria.*
### Appendix A: Nova Scotia Publicly Funded Vaccine/Immunoglobulin Eligibility

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>National Active Immunizing Agent (Type)</th>
<th>Vaccine Products e.g.</th>
<th>Eligibility</th>
</tr>
</thead>
</table>
| HPV          | Human papillomavirus                    | Gardasil              | • Grade 7 students (school-based immunization program)  
               |                                        |                       | • Females: Youth who have missed or refused HPV vaccine as part of the school-based program less than 19 years of age  
               |                                        |                       | • Males: Youth who have missed or refused HPV vaccine as part of the school-based program (beginning September 2015) less than 19 years of age  
               |                                        |                       | • Men who have sex with men- for those less than 46 years of age  
               |                                        |                       | • *Pre-exposure immunization for the following high-risk condition:  
<pre><code>           |                                        |                       |   o HIV- for those less than 46 years of age |
</code></pre>
<p>| Inf          | Influenza - inactivated                 | Fluzone               | • Quadrivalent standard dose products: Residents and non-residents of NS, 6 months of age and older |
|                                        | FluLaval Tetra        |  |
|                                        | Fluzone High-Dose     | • Quadrivalent high-dose product: Individuals 65 years of age and older. |
| IPV          | Inactivated polio                       | Imovax Polio          | • Immunization of adults who are unimmunized or have incomplete immunization with polio vaccine or combination vaccines such as Tdap-IPV. |</p>
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>National Active Immunizing Agent (Type)</th>
<th>Vaccine Products e.g.</th>
<th>Eligibility</th>
</tr>
</thead>
</table>
| Men-B        | Meningococcal B                        | Bexsero               | - **Post-exposure immunization** for Serotype B invasive meningococcal disease  
|              |                                        |                       | - Individuals who have recovered from Serotype B invasive meningococcal disease  
|              |                                        |                       | - Outbreak control  
|              |                                        |                       | - **Pre-exposure immunization for the following high-risk conditions:**  
|              |                                        |                       |   - Congenital immunodeficiency  
|              |                                        |                       |   - Hematopoietic stem cell transplant (HSCT)  
|              |                                        |                       |   - HIV  
|              |                                        |                       |   - Immunosuppressive therapy using eculizumab (Solaris)  
|              |                                        |                       |   - Solid organ transplant  
|              |                                        |                       |   - **Spleenic disorders** including sickle cell disease or other hemoglobinopathies  
|              |                                        |                       |   - Youth less than 26 years of age moving into congregate-living settings for the first time:  
|              |                                        |                       |     - Those entering post-secondary studies and living in a congregate-living setting.  
|              |                                        |                       |     - First time military trainees who will be living in a military congregate-living setting.  
|              |                                        |                       |     - Those living in a youth congregate living setting not otherwise defined e.g., Nova Scotia Youth Centre, youth community residential setting, or youth shelter, etc.  
| Men-C-C      | Meningococcal - Conjugate              | NeisVac-C Menjugate   | - Routine immunization of children less than 5 years of age  
|              |                                        |                       | - **Post-exposure immunization** for Serotype C  
|              |                                        |                       | - Outbreak control  

*Refer to the publicly funded vaccine eligibility for individuals at high risk of acquiring vaccine preventable disease policy for eligibility criteria.*
Publicly Funded Vaccine/Immunoglobulin Eligibility Policy 2023

Appendix A: Nova Scotia Publicly Funded Vaccine/Immunoglobulin Eligibility

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>National Active Immunizing Agent (Type)</th>
<th>Vaccine Products e.g.</th>
<th>Eligibility</th>
</tr>
</thead>
</table>
| Men-C-ACWY   | Meningococcal - Conjugate              | Menveo Menactra       | - Grade 7 students (school-based immunization program)
|              |                                        | Nimenrix              | - Youth who have missed or refused meningococcal vaccine as part of the school-based program less than 19 years of age
|              |                                        |                       | - Post-exposure immunization for Serotypes A, C, W, Y
|              |                                        |                       | - Outbreak control
|              |                                        |                       | - *Pre-exposure immunization for the following high-risk conditions:
|              |                                        |                       |   - Congenital immunodeficiency
|              |                                        |                       |   - Hematopoietic stem cell transplant (HSCT)
|              |                                        |                       |   - HIV
|              |                                        |                       |   - Immunosuppressive therapy using eculizumab (Solaris)
|              |                                        |                       |   - Solid organ transplant
|              |                                        |                       |   - Splenic disorders including sickle cell disease or other hemoglobinopathies
| MMR          | Measles, mumps, rubella                | MMR 11 Priorix        | - Routine immunization of children if not receiving MMRV.
|              |                                        |                       | - Immunization of children 6 months to less than 12 months of age travelling to regions where measles is endemic or there is substantial community-based transmission during an outbreak. (Consult local public health if unsure) (https://travel.gc.ca/travelling/health-safety/travel-health-notices)
|              |                                        |                       | - Adults born in 1970 or later who have not had measles disease or mumps disease or received two doses of measles or mumps containing vaccine
|              |                                        |                       | - Post-partum women who are found to be non-immune to rubella
|              |                                        |                       | - Post-exposure immunization (Measles, Mumps and Rubella)
|              |                                        |                       | - Outbreak control
|              |                                        |                       | - *Pre-exposure immunization for the following high-risk conditions once immunocompetent:
|              |                                        |                       |   - Hematopoietic stem cell transplant (HSCT)
|              |                                        |                       |   - HIV
|              |                                        |                       |   - Immunosuppressive therapy
|              |                                        |                       |   - Solid organ transplant

*Refer to the publicly funded vaccine eligibility for individuals at high risk of acquiring vaccine preventable disease policy for eligibility criteria.
### Publicly Funded Vaccine/Immunoglobulin Eligibility Policy 2023

**Appendix A: Nova Scotia Publicly Funded Vaccine/Immunoglobulin Eligibility**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>National Active Immunizing Agent (Type)</th>
<th>Vaccine Products e.g.</th>
<th>Eligibility</th>
</tr>
</thead>
</table>
| **MMRV**     | Measles, mumps, rubella & varicella    | Priorix Tetra         | - Routine immunization of children, less than 13 years of age, born 2006 and later and not previously immunized with MMR and Varicella are eligible for 2 doses  
- *Pre-exposure for the following high-risk conditions in children less than 13 years of age, once immunocompetent:*  
  - Hematopoietic stem cell transplant (HSCT)  
  - HIV  
  - Immunosuppressive therapy  
  - Solid organ transplant |
| **Var**      | Varicella                              | Varilrix Varivax      | - Routine immunization of children not receiving MMRV  
- Individuals born 1996-2005 are eligible for one dose (the first dose) of varicella vaccine  
Individuals born in 2006 and later are eligible for 2 doses of varicella vaccine if not receiving MMRV  
- **Post-exposure immunization**  
- *Pre-exposure immunization for the following high-risk conditions once immunocompetent* (if not receiving MMRV):  
  - Hematopoietic stem cell transplant (HSCT)  
  - HIV  
  - Immunosuppressive therapy  
  - Solid organ transplant  
- *Pre-exposure immunization for the following high-risk conditions (if not receiving MMRV)*:  
  - Chronic renal disease  
  - Chronic salicylate therapy  
  - Cystic fibrosis  
  - Splenic disorders  
- Pre-exposure immunization for others (if not receiving MMRV):  
  - Non-immune health care workers  
  - Post-partum women who are found to be non-immune to varicella  
  - Non-immune individuals who live with or care for anyone in the following categories:  
    ✓ blood dyscrasias  
    ✓ leukemia (except Acute Lymphoblastic Leukemia)  
    ✓ lymphoma  
    ✓ other malignancies affecting the bone marrow or lymphatic system  
    ✓ other defects of cell-mediated immunity  
- Receiving treatment associated with T-cell abnormalities (e.g. intensive chemotherapy) |

*Refer to the [publicly funded vaccine eligibility for individuals at high risk of acquiring vaccine preventable disease policy](#) for eligibility criteria.*
### Publicly Funded Vaccine/Immunoglobulin Eligibility Policy 2023

**Appendix A: Nova Scotia Publicly Funded Vaccine/Immunoglobulin Eligibility**

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>National Active Immunizing Agent (Type)</th>
<th>Vaccine Products e.g.</th>
<th>Eligibility</th>
</tr>
</thead>
</table>
| Pneu-C13     | Pneumococcal-Conjugate                  | Prevnar 13            | - Routine immunization of children  
- *Pre-exposure immunization for the following high-risk conditions:  
  - Cancer  
  - Congenital immunodeficiency  
  - [Hematopoietic stem cell transplant (HSCT)](https://www.novascotia.ca/health/topics/hematopoietic-stem-cell-transplant/)  
  - HIV  
  - [Immunosuppressive therapy](https://www.novascotia.ca/health/topics/immunosuppressive-therapy/)  
  - [Solid organ transplant](https://www.novascotia.ca/health/topics/solid-organ-transplant/)  
- [Splenic disorders](https://www.novascotia.ca/health/topics/splenic-disorders/) including sickle cell disease or other hemoglobinopathies |
| Pneu-P23     | Pneumococcal - Polysaccharide           | Pneumovax 23          | - Adults 65 years and older  
- *Pre-exposure immunization for Individuals 2 years and older with the following high-risk conditions:  
  - Cancer  
  - Chronic cerebral spinal fluid (CSF) leak  
  - Chronic liver disease  
  - Chronic lung disease (not asthma)  
  - Chronic neurological conditions that may impair clearance of oral secretions  
  - Chronic renal disease  
  - Cochlear implant  
  - Congenital immunodeficiency  
  - Cystic fibrosis  
  - Diabetes  
  - Heart disease  
  - [Hematopoietic stem cell transplant (HSCT)](https://www.novascotia.ca/health/topics/hematopoietic-stem-cell-transplant/)  
  - HIV  
  - Homelessness  
  - Substance use or harmful use of alcohol  
  - [Immunosuppressive therapy](https://www.novascotia.ca/health/topics/immunosuppressive-therapy/)  
  - Residing in long term care facilities  
  - Solid organ transplant  
  - [Splenic disorders](https://www.novascotia.ca/health/topics/splenic-disorders/) including sickle cell disease or other hemoglobinopathies |

*Refer to the [publicly funded vaccine eligibility for individuals at high risk of acquiring vaccine preventable disease policy](https://www.novascotia.ca/health/topics/publicly-funded-vaccine-eligibility-policy/) for eligibility criteria.*
Publicly Funded Vaccine/Immunoglobulin Eligibility Policy 2023

Appendix A: Nova Scotia Publicly Funded Vaccine/Immunoglobulin Eligibility

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>National Active Immunizing Agent (Type)</th>
<th>Vaccine Products e.g.</th>
<th>Eligibility</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Rab</strong></td>
<td>Rabies</td>
<td>Imovax Rabies</td>
<td>• Post-exposure immunization</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Rabavert</td>
<td></td>
</tr>
<tr>
<td><strong>RV</strong></td>
<td>Rotavirus</td>
<td>RotaTeq</td>
<td>• Routine immunization of children born on or after November 1, 2019, less than 8 months of age.</td>
</tr>
</tbody>
</table>

**Other Biological Products** *(Canadian Immunization Guide)*

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>National Agent (Type)</th>
<th>Trade Name E.g.</th>
<th>Eligibility</th>
</tr>
</thead>
</table>
| **BAtx**     | Botulism antitoxin    |                 | • People with established or suspected botulism (therapeutic)  
|              |                       |                 | • Asymptomatic people strongly suspected of having eaten food contaminated with botulism toxin *(prophylaxis)* |
| **DAtx**     | Diphtheria antitoxin  |                 | Clinical suspicion of diphtheria regardless of bacteriological confirmation |
| **Ig**       | Immunoglobulin        | GamaSTAN        | **Hepatitis A**  
|              |                       |                 | • Post exposure prophylaxis for the following:  
|              |                       |                 | o Infants less than 6 months of age  
|              |                       |                 | o Immunocompromised people who may not respond to the vaccine  
|              |                       |                 | o Immunocompetent individuals 60 years of age and older  
|              |                       |                 | o Individuals with chronic liver disease  
|              |                       |                 | o People for whom Hepatitis A vaccine is contraindicated |
|              |                       |                 | **Measles (Rubeola)**  
|              |                       |                 | • Post exposure prophylaxis for the following susceptible contacts of measles:  
|              |                       |                 | o Infants less than 6 months of age  
|              |                       |                 | o Immunologically compromised individuals for whom measles vaccine is contraindicated  
|              |                       |                 | o Pregnant persons  
|              |                       |                 | o Susceptible immunocompetent people who present more than 72 hours but less than 1 week after exposure, i.e., too late for vaccine |

*Refer to the publicly funded vaccine eligibility for individuals at high risk of acquiring vaccine preventable disease policy for eligibility criteria.
Refer to the publicly funded vaccine eligibility for individuals at high risk of acquiring vaccine preventable disease policy for eligibility criteria.